MX2007004968A - Polinucleotidos y polipeptidos torc, y metodos de uso. - Google Patents
Polinucleotidos y polipeptidos torc, y metodos de uso.Info
- Publication number
- MX2007004968A MX2007004968A MX2007004968A MX2007004968A MX2007004968A MX 2007004968 A MX2007004968 A MX 2007004968A MX 2007004968 A MX2007004968 A MX 2007004968A MX 2007004968 A MX2007004968 A MX 2007004968A MX 2007004968 A MX2007004968 A MX 2007004968A
- Authority
- MX
- Mexico
- Prior art keywords
- torc
- polypeptide
- cell
- relates
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 15
- 229920001184 polypeptide Polymers 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 230000004960 subcellular localization Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 abstract 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
La presente invencion se refiere a un amplio rango de metodos que utilizan un transductor de polinucleotido relacionado con (TORC) CREB regulado, polipeptido, o anticuerpo especifico de TORC. En adicion, la invencion se refiere a composiciones de polinucleotidos relacionados con TORC, polipeptidos, o anticuerpos especificos de TORC, incluyendo variantes de secuencias de tipo silvestre de TORC. Los metodos de ejemplo incluyen un metodo para estimular un proceso relacionado con TORC en una celula, asi como un metodo para inhibir un proceso relacionado con TORC en una celula, y un metodo para inhibir los procesos relacionados con TORC en una celula. La invencion da a conocer adicionalmente metodos terapeuticos para inhibir sustancialmente el desarrollo de, o para tratar o disminuir, una enfermedad o condicion patologica en un sujeto, relacionada con un nivel anormal de un proceso activado por TORC en una celula, los cuales incluyen administrar una o mas dosis terapeuticamente efectivas al sujeto, ya sea de una sustancia que module la acumulacion de un polipeptido TORC en una region subcelular de la celula, o bien de una sustancia que inhiba la expresion de un polipeptido TORC en la celula. En un aspecto adicional, se da a conocer un metodo para identificar un agente que module la actividad de un proceso relacionado con TORC en una celula. En todavia un aspecto adicional, la invencion se refiere a un metodo para detectar la presencia o cuantificar la cantidad de un polipeptido TORC en una muestra. En un aspecto adicional, se da a conocer un metodo para determinar si la cantidad de un polipeptido TORC en una muestra difiere de la cantidad del polipeptido TORC en una referencia. Un aspecto adicional se refiere a un metodo para contribuir al diagnostico o pronostico de, o para desarrollar una estrategia terapeutica para, una enfermedad o patologia en un primer sujeto, en donde se sabe que la localizacion subcelular de un polipeptido TORC en la patologia difiere de la localizacion subcelular del polipeptido TORC en un estado no patologico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62171604P | 2004-10-25 | 2004-10-25 | |
| PCT/US2005/038207 WO2007040550A2 (en) | 2004-10-25 | 2005-10-24 | Torc polynucleotides and polypeptides, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007004968A true MX2007004968A (es) | 2007-06-15 |
Family
ID=37906586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007004968A MX2007004968A (es) | 2004-10-25 | 2005-10-24 | Polinucleotidos y polipeptidos torc, y metodos de uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090202565A1 (es) |
| EP (1) | EP1807447A2 (es) |
| JP (1) | JP2008517627A (es) |
| KR (1) | KR20070084498A (es) |
| CN (1) | CN101090912A (es) |
| AU (1) | AU2005336514A1 (es) |
| BR (1) | BRPI0517021A (es) |
| CA (1) | CA2589430A1 (es) |
| MX (1) | MX2007004968A (es) |
| RU (1) | RU2007119313A (es) |
| WO (1) | WO2007040550A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120172413A1 (en) * | 2009-06-26 | 2012-07-05 | The Salk Institute For Biological Studies | Increasing lifespan by modulating crtc expression or localization, and methods of screening for modulators of same |
| WO2012161951A1 (en) * | 2011-05-23 | 2012-11-29 | AML Therapeutics, LLC | Peptides for preventing or treating a disease or disorder associated with cbp or p300 misregulation, and methods for use and identification thereof |
| WO2013047912A1 (ja) * | 2011-09-30 | 2013-04-04 | 公益財団法人東京都医学総合研究所 | サイクリックamp応答配列結合タンパク質遺伝子解析による薬物感受性および疾患脆弱性の評価方法 |
| ITMI20120275A1 (it) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
| EP2825889A4 (en) | 2012-03-14 | 2015-10-28 | Salk Inst For Biological Studi | ADENOVIRAL TUMOR DIAGNOSIS |
| CN103884695B (zh) * | 2012-12-21 | 2016-07-13 | 武汉纺织大学 | 一种具有快速检测细菌功能的纳米纤维膜传感器及其制备方法 |
| KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
| CN113425857B (zh) * | 2013-06-17 | 2025-05-16 | 布罗德研究所有限公司 | 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途 |
| EP4043021A3 (en) | 2014-09-24 | 2022-11-23 | Salk Institute for Biological Studies | Oncolytic tumor viruses and methods of use |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| CA3013639A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
| US12195744B2 (en) * | 2017-04-18 | 2025-01-14 | University Of Iowa Research Foundation | Identification of T-cell trafficking genes and uses thereof for increasing infiltration of T-cells into solid tumors |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
| CN110006866B (zh) * | 2019-04-16 | 2022-04-22 | 杭州迈尔德生物科技有限公司 | 一种阿片类活性物质的通用检测方法及其检测试剂盒 |
| CN113528357A (zh) * | 2021-05-26 | 2021-10-22 | 广东海洋大学 | 一种利用torc1关键基因突变株靶向识别蛋白食品中特殊氨基酸产生的方法 |
| CN117715653A (zh) * | 2021-07-07 | 2024-03-15 | 爱黛儿公司 | 与社会支配性缺失或减少相关的疾病的动物模型以及用于预防或治疗所述疾病的药物组合物 |
| AU2024284143A1 (en) * | 2023-06-07 | 2025-10-23 | Fbd Biologics Limited | Engineered il-7 variants and methods of use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1611239A1 (en) * | 2003-03-26 | 2006-01-04 | Novartis AG | Cyclic amp response element activator proteins and uses related thereto |
-
2005
- 2005-10-24 MX MX2007004968A patent/MX2007004968A/es not_active Application Discontinuation
- 2005-10-24 BR BRPI0517021-4A patent/BRPI0517021A/pt not_active IP Right Cessation
- 2005-10-24 CA CA002589430A patent/CA2589430A1/en not_active Abandoned
- 2005-10-24 WO PCT/US2005/038207 patent/WO2007040550A2/en not_active Ceased
- 2005-10-24 KR KR1020077011686A patent/KR20070084498A/ko not_active Withdrawn
- 2005-10-24 RU RU2007119313/13A patent/RU2007119313A/ru not_active Application Discontinuation
- 2005-10-24 CN CNA2005800445199A patent/CN101090912A/zh active Pending
- 2005-10-24 US US11/577,961 patent/US20090202565A1/en not_active Abandoned
- 2005-10-24 EP EP05858525A patent/EP1807447A2/en not_active Withdrawn
- 2005-10-24 AU AU2005336514A patent/AU2005336514A1/en not_active Abandoned
- 2005-10-24 JP JP2007539023A patent/JP2008517627A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070084498A (ko) | 2007-08-24 |
| BRPI0517021A (pt) | 2008-09-30 |
| WO2007040550A2 (en) | 2007-04-12 |
| WO2007040550A3 (en) | 2007-06-28 |
| AU2005336514A1 (en) | 2007-05-17 |
| CA2589430A1 (en) | 2007-04-12 |
| JP2008517627A (ja) | 2008-05-29 |
| AU2005336514A8 (en) | 2008-12-11 |
| EP1807447A2 (en) | 2007-07-18 |
| CN101090912A (zh) | 2007-12-19 |
| RU2007119313A (ru) | 2008-11-27 |
| US20090202565A1 (en) | 2009-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007004968A (es) | Polinucleotidos y polipeptidos torc, y metodos de uso. | |
| Jazii et al. | Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer | |
| Tanimukai et al. | Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease | |
| EP3298160B1 (en) | Method for predicting the response of melanoma patients to targeted pharmacotherapy | |
| WO2009038689A4 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| EP2650682A1 (en) | Method for the prognosis and treatment of cancer metastasis | |
| Giovanella et al. | Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma | |
| AU2019326405A1 (en) | Methods related to bronchial premalignant lesion severity and progression | |
| CN104583422A (zh) | 标志物在诊断和治疗前列腺癌中的用途 | |
| EP3602068B1 (en) | Biomarker for predicting cognitive decline | |
| Simats et al. | Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology | |
| TW200801515A (en) | Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio- alzheimer's disease-specific molecular biomarkers (ADSMB) | |
| Dantham et al. | Plasma circulating cell-free mitochondrial DNA in the assessment of Friedreich's ataxia | |
| US20140018299A1 (en) | Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury | |
| CA2438092A1 (en) | Ttk in diagnosis and as a therapeutic target in cancer | |
| RU2007141930A (ru) | Способ in vitro идентификации соединений для лечения рака | |
| JP2002522046A (ja) | 肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法 | |
| EP2417454B1 (en) | Method for diagnosing and/or typing renal cell carcinoma | |
| WO2009068423A3 (en) | Method for predicting therapy responsiveness in basal like tumors | |
| TW200643176A (en) | ZNFN3A1/breast cancer related gene ZNFN3A1 | |
| Zhou et al. | Elevated expression of Tweety homologue 3 predicts poor clinical outcomes in ovarian cancer | |
| US20240369578A1 (en) | Peptide t14 for braak staging | |
| JP2007515940A5 (es) | ||
| WO2004020607A3 (en) | SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| TWI498564B (zh) | 用以評估腫瘤增生、侵犯或轉移風險之生物標記及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |